13:19:12 EDT Mon 21 Oct 2019
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
GeneNews Ltd (2)
Symbol C : GEN
Shares Issued 143,588,177
Close 2018-09-21 C$ 0.06
Recent Sedar Documents

GeneNews director, CFO Auld resigns

2018-09-24 10:59 ET - News Release

Mr. James Howard-Tripp reports

GENENEWS ANNOUNCES RESIGNATION OF LESLIE AULD AS CFO AND DIRECTOR AND APPOINTMENT OF WARREN WHITEHEAD AS CHIEF ACCOUNTANT.

Leslie Auld has resigned as chief financial officer and director of GeneNews Ltd., and the company has appointed Warren Whitehead as chief accountant. Ms. Auld is leaving to pursue another opportunity.

"The board of directors thanks Leslie very much for the many years of stalwart service in helping to build GeneNews," commented James R. Howard-Tripp, chairman and chief executive officer. "We wish her all success in her new position.

"Warren Whitehead, who is the chairman of Plantform Corp. and chair of the audit committee of Aptose Biosciences, as well as having held the role of CFO in multiple companies, is joining GeneNews to guide the expanded cross-border team that will manage the financial reporting, as well as financing activities, as GeneNews strengthens its position as the pioneer of early cancer diagnosis. Warren and I have worked together twice before and look forward to doing so again."

Warren Whitehead

Mr. Whitehead is a chartered professional accountant (CPA) and a certified management accountant (CMA) who has held several senior financial management positions with pharmaceutical and biotechnology firms. He is the former CFO of Promis Neurosciences Inc. (Toronto Stock Exchange); former CFO of Arius Research Inc. (TSX), providing financial guidance and leadership during the acquisition of Arius by Roche in 2008; former CFO of Labopharm Inc. (TSX, Nasdaq Stock Market), where he completed a series of public equity financings including a cross-border Nasdaq offering.

About GeneNews Ltd.

GeneNews, an innovator in the liquid biopsy space, is committed to becoming a leader in advanced diagnostics and personalized medicine, serving as a strong commercialization outlet for early detection of cancer and other chronic diseases. The company's mission is to identify, assess and make commercially available a comprehensive menu of diagnostics that provides physicians and patients with personalized clinical intelligence and actionable information to improve health outcomes through the early diagnosis of disease.

We seek Safe Harbor.

© 2019 Canjex Publishing Ltd. All rights reserved.